Cargando…
Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study
PURPOSE: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. METHODS: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers in eastern India between October 2020 and April...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391460/ https://www.ncbi.nlm.nih.gov/pubmed/37203069 http://dx.doi.org/10.4103/IJO.IJO_2688_22 |
_version_ | 1785082713339854848 |
---|---|
author | Chakraborty, Debdulal Mondal, Soumen Sengupta, Sabyasachi Abbas, Zahir Chandra, Khushboo Boral, Subhendu Maiti, Aniruddha Roy, Sangeeta Mukherjee, Angshuman Das, Arnab Chakraborty, Somnath Nag, Pinaki |
author_facet | Chakraborty, Debdulal Mondal, Soumen Sengupta, Sabyasachi Abbas, Zahir Chandra, Khushboo Boral, Subhendu Maiti, Aniruddha Roy, Sangeeta Mukherjee, Angshuman Das, Arnab Chakraborty, Somnath Nag, Pinaki |
author_sort | Chakraborty, Debdulal |
collection | PubMed |
description | PURPOSE: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. METHODS: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers in eastern India between October 2020 and April 2022 were included. RESULTS: Of 758 injections given during the study period across centers, 13 IOI events (1.7%) were recorded attributable to brolucizumab. The IOI occurred after the first dose in two eyes (15%) (median 45 days after brolucizumab), second dose in six eyes (46%) (median = 8.5 days), and third dose (39%) in the remaining five eyes (median 7 days). Reinjections of brolucizumab were administered at a median interval of 6 weeks (interquartile range = 4–10 weeks) in the 11 eyes, where IOI occurred after the second or third dose. Eyes that experienced IOI after the third dose had received a significantly greater number of previous antivascular endothelial growth factor injections (median = 8) compared to those who developed it after the first or second dose (median = 4) (P = 0.001). Anterior chamber cells were seen in almost all eyes (n = 11, 85%), while peripheral retinal hemorrhages were seen in two eyes, and one eye showed branch artery occlusion. Two-thirds of patients (n = 8, 62%) recovered with a combination of topical and oral steroids, while remaining recovered with topical steroids alone. Irreversible visual loss was not seen in any eye, and median vision recovered to pre-IOI levels by 3 months’ time point. CONCLUSION: Brolucizumab-induced IOI was relatively rare, occurring in 1.7% of eyes, was more common after the second or third injection, especially in those who required frequent reinjections every 6 weeks, and occurred earlier with increasing number of previous brolucizumab injections. Continued surveillance is necessary even after repeated doses of brolucizumab. |
format | Online Article Text |
id | pubmed-10391460 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-103914602023-08-02 Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study Chakraborty, Debdulal Mondal, Soumen Sengupta, Sabyasachi Abbas, Zahir Chandra, Khushboo Boral, Subhendu Maiti, Aniruddha Roy, Sangeeta Mukherjee, Angshuman Das, Arnab Chakraborty, Somnath Nag, Pinaki Indian J Ophthalmol Original Article PURPOSE: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. METHODS: All consecutive patients diagnosed with brolucizumab-induced IOI from 10 centers in eastern India between October 2020 and April 2022 were included. RESULTS: Of 758 injections given during the study period across centers, 13 IOI events (1.7%) were recorded attributable to brolucizumab. The IOI occurred after the first dose in two eyes (15%) (median 45 days after brolucizumab), second dose in six eyes (46%) (median = 8.5 days), and third dose (39%) in the remaining five eyes (median 7 days). Reinjections of brolucizumab were administered at a median interval of 6 weeks (interquartile range = 4–10 weeks) in the 11 eyes, where IOI occurred after the second or third dose. Eyes that experienced IOI after the third dose had received a significantly greater number of previous antivascular endothelial growth factor injections (median = 8) compared to those who developed it after the first or second dose (median = 4) (P = 0.001). Anterior chamber cells were seen in almost all eyes (n = 11, 85%), while peripheral retinal hemorrhages were seen in two eyes, and one eye showed branch artery occlusion. Two-thirds of patients (n = 8, 62%) recovered with a combination of topical and oral steroids, while remaining recovered with topical steroids alone. Irreversible visual loss was not seen in any eye, and median vision recovered to pre-IOI levels by 3 months’ time point. CONCLUSION: Brolucizumab-induced IOI was relatively rare, occurring in 1.7% of eyes, was more common after the second or third injection, especially in those who required frequent reinjections every 6 weeks, and occurred earlier with increasing number of previous brolucizumab injections. Continued surveillance is necessary even after repeated doses of brolucizumab. Wolters Kluwer - Medknow 2023-05 2023-05-17 /pmc/articles/PMC10391460/ /pubmed/37203069 http://dx.doi.org/10.4103/IJO.IJO_2688_22 Text en Copyright: © 2023 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Chakraborty, Debdulal Mondal, Soumen Sengupta, Sabyasachi Abbas, Zahir Chandra, Khushboo Boral, Subhendu Maiti, Aniruddha Roy, Sangeeta Mukherjee, Angshuman Das, Arnab Chakraborty, Somnath Nag, Pinaki Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
title | Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
title_full | Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
title_fullStr | Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
title_full_unstemmed | Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
title_short | Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study |
title_sort | incidence, clinical features, risk factors, and outcomes of intraocular inflammation following brolucizumab in indian eyes – a multicentric study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391460/ https://www.ncbi.nlm.nih.gov/pubmed/37203069 http://dx.doi.org/10.4103/IJO.IJO_2688_22 |
work_keys_str_mv | AT chakrabortydebdulal incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT mondalsoumen incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT senguptasabyasachi incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT abbaszahir incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT chandrakhushboo incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT boralsubhendu incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT maitianiruddha incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT roysangeeta incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT mukherjeeangshuman incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT dasarnab incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT chakrabortysomnath incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy AT nagpinaki incidenceclinicalfeaturesriskfactorsandoutcomesofintraocularinflammationfollowingbrolucizumabinindianeyesamulticentricstudy |